Soldan sağa şantlı doğumsal kalp hastalıklı çocuklarda şant miktarı ile kardiyotrofin–1 ilişkisi
Amaç: Çalışmamızda çocuklarda soldan sağa şantlı doğumsal kalp hastalıklarında serum kardiyotrofin-1 (CT-1) düzeyleri ile şant miktarının karşılıklı etkileşimlerini araştırmak, bu belirtecin intrakardiyak defekt tipine göre değişimlerini incelemek amaçlanmıştır. Gereç ve Yöntem: Çalışmamızda, 1 ay–13 yaşları arasında, 45 hasta ve 23 sağlıklı çocuk incelendi. Hasta grubu içinde 19 olguda atriyal septal defekt (ASD), 17 olguda ventriküler septal defekt (VSD), 6 olguda ASD ve VSD (ASD+VSD) ve 3 olguda patent duktus arteriyozus (PDA) mevcuttu. Tüm çocuklara konvansiyonel ekokardiyografi incelemesi (iki boyutlu, M-Mode, iki boyutlu Doppler ve renkli Doppler ekokardiyografileri) yapıldı. Tüm olgulardan ekokardiyografi çalışmaları ile eş zamanlı olarak plazma BNP düzeyleri kemilüminisans ve CT-1 düzeyleri de “enzyme-linked immunosorbent assay” (ELISA) yöntemleriyle ölçüldü. Bulgular: Hasta grubunda CT-1 ile şant miktarı arasında (p
THE RELATIONSHIP BETWEEN LEFT TO RIGHT SHUNTING CONGENITAL HEART DISEASE AND CARDIOTROPHIN-1 IN CHILDREN
Objective: In our study, it was aimed to investigate the interaction of serum cardiotrophin-1 (CT-1) levels in left to right shunting congenital heart disease in children and to evaluate the change of this biomarker with intracardiac defect features.Material and Method: We investigated 45 patients and 23 healthy children between 1 months and 13 years of age in our study. In the patient group, we identified an atrial septal defect (ASD) in 19 cases, a ventricular septal defect (VSD) in 17 cases, an ASD and VSD (ASD+VSD) in 6 cases and a patent ductus arteriosus (PDA) in 3 cases. All children underwent a classical echocardiography (twodimensional, M-Mode, two-dimensional Doppler and colour Doppler echocardiography). In all patients, plasma BNP levels were measured by chemiluminescence and CT-1 levels were estimated by enzyme-linked immunosorbent assay (ELISA) method, synchronously with echocardiographic studies. Results: A positive correlation was detected between CT-1 and the number of shunts (p
___
- Hsu DT, Pearson GD. Heart failure in children: part
I: history, etiology, and pathophysiology.
Circulation 2009;2(1):63-70.
- Kuwahara K, Saito Y, Harada M ve ark.
Involvement of cardiotrophin-1 in cardiac
myocyte-nonmyocyte interactions during
hypertrophy of rat cardiac myocytes in vitro.
Circulation. 1999;100(10):1116-24.
- Freed DH, Moon MC, Borowiec AM ve ark.
Cardiotrophin-1: expression in experimental
myocardial infarction and potential role in post-MI
wound healing. Mol Cell Biochem. 2003;254:247-56.
- Freed DH, Borowiec AM, Angelovska T ve ark.
Induction of protein synthesis in cardiac fibroblasts
by cardiotrophin-1: integration of multiple
signaling pathways. Cardiovasc Res. 2003;60:365-
75.
- Latchman DS. Cardiotrophin-1 (CT-1): a novel
hypertrophic and cardioprotective agent. Int J Exp
Pathol. 1999;80:189-196.
- Jougasaki M, Tachibana I, Luchner A ve ark.
Augmented cardiac cardiotrophin-1 in
experimental congestive heart failure. Circulation.
2000;101:14-7.
- Berezin AE.Prognostication in different heart
failure phenotypes: The Role of Circulating
Biomarkers. J Circ Biomark. 2016; 16:6.
- Pennica D, King KL, Shaw KJ ve ark. Expression
cloning of cardiotrophin 1, a cytokine that induces
cardiac myocyte hypertrophy. Proc Natl Acad Sci
USA. 1995;92:1142-46.
- Stephanou A, Brar B, Heads R ve ark.
Cardiotrophin-1 Induces Heat Shock Protein
Accumulation in Cultured Cardiac Cells and
Protects them from Stressful Stimuli. J Mol Cell
Cardiol. 1998;30:849-55.
- Wollert K, Taga T, Saito M ve ark. Cardiotrophin-1
activates a distinct form of cardiac muscle cell
hypertrophy. Assembly of sarcomeric units in
series VIA gp130/leukemia inhibitory factor
receptor-dependent pathways. J Biol Chem.
1996;271:9535-45.
- Talwar S, Downie P, Squire I ve ark. An
immunoluminometric assay for cardiotrophin-1: a
newly identified cytokine is present in normal
human plasma and is increased in heart failure.
Biochem Biophys Res Commun. 1999;261:567-71
- Lorenzo-Almorós A, Tuñón J, Orejas M, Cortés M,
Egido J, Lorenzo Ó. Diagnostic approaches for
diabetic cardiomyopathy. Cardiovasc Diabetol.
2017;16:28.
- Tsutamoto T, Asai S, Tanaka T ve ark. Plasma level
of cardiotrophin-1 as a prognostic predictor in
patients with chronic heart failure. Eur J Heart Fail.
2007;9:1032-7.
- Cantinotti M, Giovannini S, Murzi B ve ark.
Diagnostic, prognostic and therapeutic relevance
of B-type natriuretic hormone and related peptides
in children with congenital heart diseases. Clin
Chem Lab Med. 2011;49:567-80.
- Jougasaki M. Cardiotrophin-1 in cardiovascular
regulation. Adv Clin Chem. 2010;52:41-76.
- Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka
K, Kageyama M, Nakagawa N, Seino Y. Plasma
brain natriuretic peptide and the evaluation of
volume overloadm in infants and children with
congenital heart disease. Acta Med Okayama.
2003;57:191-7.
- Gonzalez A, Lopez B, Martín-Raymondi D ve ark.
Usefulness of plasma cardiotrophin-1 in
assessment of left ventricular hypertrophy
regression in hypertensive patients. J Hypertens.
2005;23:2297-304.
- Lopez B, Gonzalez A, Lasarte JJ ve ark. Is plasma
cardiotrophin-1 a marker of hypertensive heart
disease? J Hypertens. 2005;23:625-32.
- Monserrat L, Lopez B, Gonzalez A ve ark.
Cardiotrophin-1 plasma levels are associated with
the severity of hypertrophy in hypertrophic
cardiomyopathy. Eur Heart J. 2011;32:177-83.
- Talwar S, Squire IB, Downie PF ve ark. Elevated
circulating cardiotrophin-1 in heart failure:
relationship with parameters of left ventricular
systolic dysfunction. Clin Sci. 2000;99:83-8.
- Tsutamoto T, Wada A, Maeda K ve ark.
Relationship between plasma level of
cardiotrophin-1 and left ventricular mass index in
patients with dilated cardiomyopathy. J Am Coll
Cardiol. 2001;38:1485-90.
- Tsutamoto T, Asai S, Tanaka T ve ark. Plasma level
of cardiotrophin-1 as a prognostic predictor in
patients with chronic heart failure. Eur J Heart Fail.
2007;9:1032-7.